Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 4/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.42 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066041 | 1.00 | F2 (0.51) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL30718534 | 0.88 | F2 (0.49) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL30718508 | 0.87 | F2 (0.48) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL30718544 | 0.86 | F2 (0.47) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL29913751 | 0.85 | F2 (0.52) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL29913761 | 0.84 | F2 (0.48) | F2ALDH1A1CA2SPPL2A | |
| SCHEMBL29913816 | 0.84 | F2 (0.46) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL30718528 | 0.83 | F2 (0.45) | F2ALDH1A1CA12CA2CA7 | |
| SCHEMBL29913880 | 0.81 | F2 (0.49) | F2LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL8178414 | 0.79 | F2 (0.54) | F2ALDH1A1CA12CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877474-B1 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LTD (IN) | 2020-11-04 | — | — | EP | claimed |
| EP-2877474-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | Laurus Labs Private Limited (IN) | 2015-06-03 | — | — | EP | claimed |
| WO-2014016660-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2014-01-30 | — | — | WO | claimed |
| EP-3795572-B1 | DARUNAVIR PROPIONATE SOLVATE | LAURUS LABS LTD (IN) | 2023-11-15 | — | — | EP | disclosed |
| EP-3795572-A1 | DARUNAVIR PROPIONATE SOLVATE | Laurus Labs Limited (IN) | 2021-03-24 | — | — | EP | disclosed |
| EP-2877474-B1 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LTD (IN) | 2020-11-04 | — | — | EP | disclosed |
| EP-2477992-B1 | PROCESSES FOR THE PREPARATION OF DARUNAVIR AND THE AMORPHOUS FORM THEREOF | MYLAN LABORATORIES LTD (IN) | 2016-12-14 | — | — | EP | disclosed |
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS LIMITED (IN) | 2016-12-08 | — | — | US | disclosed |
| EP-2877474-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | Laurus Labs Private Limited (IN) | 2015-06-03 | — | — | EP | disclosed |
| US-8703980-B2 | Process for the preparation of darunavir | TIANISH LABORATORIES PRIVATE LIMITED (IN) | 2014-04-22 | — | — | US | disclosed |
| WO-2014016660-A2 | A PROCESS FOR PREPARATION OF DARUNAVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2014-01-30 | — | — | WO | disclosed |
| WO-2013114382-A1 | CRYSTALLINE DARUNAVIR | MYLAN LABORATORIES LTD (IN) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013011485-A1 | PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2013-01-24 | — | — | WO | disclosed |
| EP-1725566-B1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARM LTD (IE) | 2009-06-17 | — | — | EP | disclosed |
| EP-1725566-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | Tibotec Pharmaceuticals Ltd. (IE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005063770-A1 | PROCESS FOR THE PREPARATION OF (3R,3AS,6AR)-HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355525-A1 | PROCESS FOR PREPARATION OF DARUNAVIR | SAMHD1, CYP3A5, DARS1 | F2 3943/4885ALDH1A1 1810/4885CA12 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.